Exposure (AUC and Cmax; mean ± S.D.) of cobimetinib in FVB (WT) and Cyp3a−/− mice with and without treatment with itraconazole (n = 3–6 mice/group)
| Cobimetinib (Oral) | FVB | Cyp3a−/− | ||
|---|---|---|---|---|
| No Treatment | Itraconazole | No Treatment | Itaconazole | |
| AUC(0-tlast) (μM/h) | 1.38 ± 0.25 | 8.03 ± 1.06* | 6.42 ± 1.07 | 10.7 ± 2.9 |
| Cmax (μM) | 0.175 ± 0.041 | 0.509 ± 0.065* | 0.479 ± 0.077 | 0.644 ± 0.355 |
↵* P < 0.05 compared with corresponding control animals.